The United States Food and Drugs Administration (USFDA) has conducted an inspection at Unit-2 of Shilpa Medicare’s wholly owned subsidiary -- Shilpa Pharma Lifesciences, located at Raichur. The inspection was conducted from March 10th to 14th, 2025.
The inspection was closed with ZERO observations. This is second consecutive ZERO 483 inspection from USFDA at this site.
Shilpa Medicare produces and exports consistently high-quality Active Pharmaceutical Ingredients Fine Chemicals, intermediates, herbal products and speciality chemical products using sophisticated technology, meticulously following international specifications.
